To evaluate the efficacy and safety of once-weekly DPP-4 inhibitor: Omarigliptin and the differences between Omarigliptin and once or twice-daily DPP-4 inhibitors for the treatment of type 2 diabetes - To evaluate the efficacy of Omarigliptin and the differences between Omarigliptin and daily DPP-4 inhibitors

Omarigliptin tended to elicit reductions in FBG, LDL-C, TG, AST, ALT, gamma-GTP, ACR with log ACR, and SBP and DBP, but the differences did not reach statistical significance compared with control. Values for HDL-C tended to increase, but also did not reach statistical significance compared with control. Omarigliptin significantly decreased HOMA-IR, RLP-C, and hsCRP with log hsCRP compared with control. However, omarigliptin did not affect HbA1c, BMI, and eGFR.